Introduction
============

A growing amount of evidence has shown that virus infection, directly or indirectly, can result in numerous malignant tumors.[@b1-ott-9-7105] Worldwide, annually, \>550,000 new patients suffering from malignant tumors are associated with human papillomaviruses (HPVs) infection.[@b2-ott-9-7105],[@b3-ott-9-7105] Currently, \>150 HPV subtypes with 15 species of high-risk types of HPV (HR-HPV) have been found. The HR-HPV family contains HPV16, HPV18, HPV31, HPV33, HPV35, HPV39, HPV45, HPV51, HPV52, HPV56, HPV58, HPV59, HPV66, and HPV68. HPV16 and HPV18 are the most common cancer-causing HPV subtypes on a global scale.[@b2-ott-9-7105],[@b3-ott-9-7105] Simultaneously, HPV16, HPV18, and HPV33 have been confirmed to be correlated with tumors in digestive system, such as oral cancer, esophageal cancer, and colorectal cancer.[@b1-ott-9-7105],[@b4-ott-9-7105],[@b5-ott-9-7105] In 2012, 1 million new cases of gastric cancer (GC) occurred (952,000 cases, 6.8% of the total), leading to its rank as the fifth most common malignant tumor worldwide, following lung, breast, colorectum, and prostate cancers. More than 70% of cases (677,000 cases) occurred in the developing countries (456,000 in males and 221,000 in females), and worldwide, half of all the GCs occurred in Eastern Asia (mostly in China). The fatality rate of GC was ranked third, following only lung and liver cancers.[@b6-ott-9-7105] In 2015, cancer statistics estimated that new cancer cases and deaths from GC numbered 24,590 and 10,720 (1.48% and 1.82% of the total, respectively) in the USA.[@b7-ott-9-7105]

Several meta-analyses have shown that HPV infection is a high-risk factor for carcinogenesis at some anatomic sites, including the skin, genital tract, respiratory tract, and disparate anatomic sites of the digestive tract.[@b8-ott-9-7105]--[@b11-ott-9-7105] With the assumption that repeatedly persistent infection with HPV can cause dysplasia or adenocarcinoma in situ, as precursor lesions, it will eventually result in malignant transformation.[@b12-ott-9-7105] Some studies have investigated HPV infection in gastrointestinal cancer.[@b4-ott-9-7105],[@b5-ott-9-7105],[@b8-ott-9-7105],[@b12-ott-9-7105]--[@b14-ott-9-7105] However, only sporadic research has reported the HPV prevalence in GC. Currently, whether there is a link between HPV infection and GC occurrence has not been systematically analyzed publicly.

In order to obtain insight into the HPV prevalence in GC tissues, the present meta-analysis was conducted, and this study facilitates and improves the understanding of the carcinogenicity of the virus in GC and provides new clues to GC etiology and prevention.

Materials and methods
=====================

Search strategy
---------------

The PubMed, EMBASE, Web of Science, Science Direct, Ovid, Wiley Online Library, and Cochrane Library databases, as well as the China National Knowledge Infrastructure, Chinese Chongqing VIP, Chinese Wan Fang, and China Biology Medicine databases, were searched to identify all the appropriate studies published on or before June 3, 2016, with the following search strategy: (HPV OR human papillomavirus) AND (gastric OR stomach OR cardia OR gastrointestinal) AND (adenocarcinoma OR carcinoma OR cancer OR neoplasm OR tumour OR tumor OR neoplasm\* OR malignan\*).

Study selection and inclusion criteria
--------------------------------------

The inclusion criteria for this meta-analysis are as follows: 1) studies had to estimate the prevalence of HPV in GC cases where the classification was unspecified or provide sufficient information; 2) data from case reports, review articles, meeting abstracts, unpublished reports, and letters were not eligible for this study; 3) studies had to investigate HPV DNA in human GC tissue; two cohort studies detecting HPV serum antibodies in patients with GC were excluded;[@b13-ott-9-7105],[@b15-ott-9-7105] 4) only English- or Chinese-language studies could be included; and 5) the HPV detection methods used were polymerase chain reaction (PCR) and in situ hybridization (ISH).

In addition, if two or more articles were published by the same group with the same case series, the one with larger sample size was selected. The research was conducted independently by two investigators, and disagreements were resolved by discussion or consulting with a third reviewer ([Figure 1](#f1-ott-9-7105){ref-type="fig"}).

Data extraction
---------------

The following data were extracted from the eligible studies: name of first author, published year, country, anatomic site, language, sample size (n), HPV DNA test method, materials, number of cases and controls; HPV subtype-specific, mean age, sex, pathological differentiation, and clinical stage (TNM) of GC.

Statistical analysis
--------------------

Pooled HPV prevalence and pooled odds ratios (ORs) with their 95% confidence intervals (CIs) were used to evaluate the relation of HPV infection with the occurrence and development of GC. The STATA software, Version 12.0, was applied to analyze the eligible literature using the meta-module "meta" or "metan" command. Estimates, standard errors, and 95% CIs were used to calculate the HPV prevalence percentages in all the studies. ORs and 95% CIs were measured among 15 case--control studies, and pooled HPV prevalence and 95% CIs were computed among all the 30 studies. All the prevalence estimates were transformed logarithmically, which necessitated adding a correction factor of 0.5 to both the numerator and denominator for reported prevalence of 0. In these situations, inverse variance, Mantel--Haenszel (M--H) method, and DerSimonian and Laird (D+L) method required the addition of a small quantity (usually 0.5) to the cell counts in order to avoid division by zero errors. The pooled estimates were computed by using the Mantel--Haenszel method, assuming a fixed effects model or the random effects model of the D+L method. When significant heterogeneity occurred in the pooled estimates across studies, a random effects model was considered. In addition, heterogeneity was described by using the *I*^2^ statistic. Meta-regression models were estimated by the "metareg" command to analyze the heterogeneity of the pooled HPV prevalence in GC. Begg's test ("metabias") was accepted to draw funnel plots and describe the publication bias of funnel plot asymmetry (publication bias). The "metainf" command was selected to assess the influence of individual studies on the effect estimate. *P*\<0.05 was considered to be statistically significant. The source of heterogeneity was explored by using the following approaches: sensitivity analysis, subgroup analysis, meta-regression, and the random effects model.

Results
=======

Eligible studies
----------------

The flowchart shows a diagram of all the studies included in this meta-analysis ([Figure 1](#f1-ott-9-7105){ref-type="fig"}). On the basis of the primary search strategy, a total of 13,101 related publications were identified. After browsing through the titles and abstracts, 116 references were deemed as eligible based on the selection and inclusion criteria. Through a strict review of the complete articles, 86 studies were excluded, including 57 studies without sufficient information, 4 studies conducted in mouse models, 23 reduplicated studies, and 2 studies detecting HPV serum antibody in GC. As a result, 30 eligible studies were included in this meta-analysis; of them, 10 were in English and 20 in Chinese, and they involved a total of 1,917 GC cases and 576 controls. Half of the 30 studies were case--control studies, and the remaining were case-only studies; the 15 case--control studies included 944 cases and corresponding 576 controls ([Table 1](#t1-ott-9-7105){ref-type="table"}).

Study characteristics
---------------------

Among the 30 studies, 25 were conducted in China. The materials included fresh-frozen (FF) and formalin-fixed paraffin-embedded (FFPE) tissue. Moreover, a PCR-based technique was adopted to detect HPV DNA in 26 studies, whereas only 4 studies used ISH to detect HPV *E6/E7* genes ([Table 1](#t1-ott-9-7105){ref-type="table"}). In addition, 15 studies provided the prevalence of HPV in different histological differentiations of patients with GC, which were divided into well-differentiated, moderately differentiated, poorly differentiated, and undifferentiated grades.[@b16-ott-9-7105]--[@b30-ott-9-7105] Some studies provided concrete information about HPV prevalence in different clinical stages (TNM: I, II, III, and IV),[@b16-ott-9-7105],[@b19-ott-9-7105],[@b27-ott-9-7105],[@b31-ott-9-7105],[@b32-ott-9-7105] the age and sex[@b15-ott-9-7105],[@b16-ott-9-7105],[@b18-ott-9-7105],[@b19-ott-9-7105],[@b25-ott-9-7105],[@b27-ott-9-7105],[@b32-ott-9-7105] of the patients, and specific HPV types (HPV16 and HPV18).[@b15-ott-9-7105],[@b16-ott-9-7105],[@b20-ott-9-7105]--[@b24-ott-9-7105],[@b29-ott-9-7105]--[@b31-ott-9-7105],[@b33-ott-9-7105]--[@b39-ott-9-7105] [Table 1](#t1-ott-9-7105){ref-type="table"} provides the information about the studies. The sample sizes of the 30 eligible studies ranged from 30 (cases/controls: 15/15) to 236 (cases/controls: 132/104).

The overall HPV prevalence in GC
--------------------------------

The HPV prevalence percentage was represented by decimals over forest plots. [Figure 1](#f1-ott-9-7105){ref-type="fig"} shows the HPV prevalence rates and 95% CI estimates from all the 1,917 GC cases, based on the D+L methods with a random effects model. The pooled HPV prevalence was 0.280 (95% CI: 0.232, 0.327), which equals a proportion of 28.0% (95% CI: 23.2%, 32.7%; *z*=11.63; *P*\<0.01). The heterogeneity between the studies was obvious (*I*^2^=96.9%, *P*\<0.01; [Figure 2](#f2-ott-9-7105){ref-type="fig"}). The 15 case--control studies were generalized to a pooled OR of 7.388 (95% CI =3.876, 14.082), based on the D+L methods with random effects model, which was statistically significant (*z*=6.08, *P*\<0.01; [Figure 3](#f3-ott-9-7105){ref-type="fig"}). This result indicated that the HPV prevalence in GC cases was 7-fold more than that in the corresponding normal gastric tissues, but the heterogeneity between these studies could not be ignored (*I*^2^=56.7%, *P*=0.004).

### The HPV prevalence in subgroups stratified by country, sample size, HPV test method, and materials

All research could be stratified by country, sample size, HPV test method, and materials ([Table 1](#t1-ott-9-7105){ref-type="table"}; [Figure 4](#f4-ott-9-7105){ref-type="fig"}). The HPV prevalence was higher in cases from China than in those from non-Chinese regions (31% vs 9%). The HPV prevalence in the gastric cardia (36%) was more common than that in overall GC (28%), and the HPV prevalence was similar in cases from FFPE and FF tumor specimens (29% vs 26%). Oddly, the ISH method yielded a higher rate of HPV infection than did the PCR method (36% vs 26%), which was in contrast to the findings of many other studies.[@b5-ott-9-7105],[@b9-ott-9-7105]--[@b11-ott-9-7105] There was no distinct difference between large samples (≥50 cases) and small samples (\<50 cases), with HPV prevalence rates of 29% and 27%, respectively.

### The HPV prevalence and its clinicopathological parameters in patients with GC

#### Age and sex

Information on age and sex was collected from 6 studies.[@b16-ott-9-7105],[@b18-ott-9-7105],[@b19-ott-9-7105],[@b25-ott-9-7105],[@b27-ott-9-7105],[@b32-ott-9-7105] HPV was positive in 75 of the 223 patients with GC aged \>50 years, whereas it was positive in 45 of the 106 patients with GC aged \<50 years. Then, a pooled OR of 0.993 (95% CI: 0.579, 1.700) was estimated by using the M-H method. There was no significant difference between HPV incidence and ages of patients with GC. Similarly, information on sex was available for 5 of the 30 studies. HPV was detected in 99 (44.4%) of the 223 male patients and in 33 (29.7%) of the 111 female patients with GC. Based on these findings, a significantly pooled OR of 1.698 (95% CI: 1.007, 2.862) was computed (*z*=1.99, *P*=0.047), which indicated that males were slightly more likely to have HPV-positive GC.

#### HPV subtypes

Sixteen studies provided data on specific HPV types (including HPV16 and HPV18).[@b15-ott-9-7105],[@b16-ott-9-7105],[@b20-ott-9-7105]--[@b24-ott-9-7105],[@b29-ott-9-7105]--[@b31-ott-9-7105],[@b33-ott-9-7105]--[@b39-ott-9-7105] HPV16 was found in 210 (21%) of the 992 GC cases, whereas HPV18 was found in 90 (7%) of the 992 GC cases, with a significant OR of 3.314 (95% CI: 1.617, 6.792). It was found that HPV16 was 3 times more frequently detected than HPV18 ([Figure 4](#f4-ott-9-7105){ref-type="fig"}).

#### Histological differentiation of GC

Fifteen studies provided the prevalence of HPV in GC of different histological differentiations, which were divided into well-differentiated, moderately differentiated, poorly differentiated, and undifferentiated GC.[@b16-ott-9-7105]--[@b30-ott-9-7105] The HPV prevalence was 30.3% (142 of 468 patients) in well-differentiated/moderately differentiated GC, whereas the HPV prevalence was 43.0% (150 of 349 patients) in poorly differentiated/undifferentiated GC, with an OR of 1.569 (95% CI: 1.148, 2.143). Therefore, there were significant associations between HPV prevalence and histological grades of GC, and poorly differentiated/undifferentiated GC patients were more likely to be HPV-positive than well-differentiated/moderately differentiated cases ([Figure 4](#f4-ott-9-7105){ref-type="fig"}).

#### Clinical stages (TNM)

Five studies provided concrete information about HPV prevalence in different clinical stages (TNM: I, II, III, IV).[@b16-ott-9-7105],[@b19-ott-9-7105],[@b27-ott-9-7105],[@b31-ott-9-7105],[@b32-ott-9-7105] The HPV prevalence was 51.0% (49 of 96 patients) in TNM I/TNM II GC patients and 40.6% (58 of 143 patients) in TNM III/TNM IV GC patients. The statistically significant pooled OR was 0.414 (95% CI: 0.223, 0.770); therefore, it was uncertain whether HPV played a prognostic role in GC.

#### HPV prevalence and *p53* gene mutation

Five studies in this meta-analysis[@b16-ott-9-7105],[@b22-ott-9-7105],[@b24-ott-9-7105],[@b37-ott-9-7105],[@b40-ott-9-7105] with 354 cases provided information about the relationship between HPV prevalence and the *p53* gene. However, the pooled OR of 1.534 (95% CI =0.752, 3.127) was insignificant.

Sensitivity analysis, meta-regression, and publication bias in case--control studies
------------------------------------------------------------------------------------

Sensitivity analysis indicated that no individual study could influence the pooled effect estimate significantly. A meta-regression analysis was performed, and it was observed that the source of heterogeneity between the studies was from the item of country (China vs non-China, *P*=0.004). Begg's test was implemented to screen for publication bias. As a result, with continuity correction (*z*=0.30, *P*\>0.767), there was no evident publication bias ([Figure 5](#f5-ott-9-7105){ref-type="fig"}).

Discussion
==========

GC is one of the most frequent cancers worldwide. Almost two-thirds of the GC cases occurred in undeveloped regions. Moreover, in 2005, 0.3 million deaths and 0.4 million new cases of GC caused it to become the third most common cancer among Chinese people.[@b41-ott-9-7105] Research conducted between 2005 and 2010 reported that the incidence and mortality of GC were 21.04% and 19.13% of all cancer-related cases and deaths, respectively, in Zhuanghe, China.[@b42-ott-9-7105] It is generally believed that gastric tumorigenesis is correlated with *Helicobacter pylori* infection.[@b43-ott-9-7105],[@b44-ott-9-7105] However, in recent years, several studies have verified that gastric carcinogenesis is also associated with Epstein--Barr virus infection.[@b43-ott-9-7105],[@b44-ott-9-7105] In the present study, it was found that HPV prevalence increased GC risk.

To date, the present study was the first meta-analysis to systematically evaluate the association between HPV prevalence and GC as well as their clinicopathological features. In this meta-analysis, a pooled HPV prevalence of 28.0% (95% CI: 23.2%, 32.7%) in 1,917 GC cases among 30 included studies was estimated, and a pooled OR of 7.388 (95% CI =3.876, 14.082) was estimated among 15 case--control studies, which demonstrated that HPV prevalence was a high-risk factor in gastric carcinogenesis.

In addition, it was found that the pooled prevalence of HPV16 was 3-fold higher than that of HPV18 (21% vs 7%) in GC. Other HPV subtypes were infrequent in GC tissues. In addition, the prevalence of HPV in gastric cardia cancer was greater than that in overall GC (36% vs 28%). If HPV could enter the pathway via an oral route from the esophagus to the stomach, a higher HPV prevalence can be expected in oral cancers than in GC. Furthermore, 15 studies, with 817 cases in total, provided data on pathological grade of differentiation, and the HPV incidence in poorly differentiated/undifferentiated GC patients was greater than that in well-differentiated/moderately differentiated GC, with an OR of 1.569. In contrast, the HPV prevalence in clinically advanced stages (TNM III/TNM IV) was slightly less than that in early stages (TNM I/TNM II; OR =0.414; 95% CI: 0.223, 0.770). Therefore, the role of HPV in the prognosis of GC remains unclear.

However, the pathogenesis of GC is multifactorial, and HPV infection might be one of the infectious risk factors. With the assumption that repeatedly persistent infection with HPV can cause dysplasia or adenocarcinoma in situ, as precursor lesions, it will eventually result in malignant transformation. Therefore, it could be hypothesized that HPV might enter the anus and colorectum, causing infection from anogenital sites. Otherwise, HPV enters orally, with downward infection from the mouth to the esophagus and finally to the stomach. It has been systematically found in reviews that HPV prevalence was related to anal, colorectal, oral, pharyngeal, and esophageal carcinogenesis.[@b1-ott-9-7105],[@b4-ott-9-7105],[@b5-ott-9-7105],[@b8-ott-9-7105],[@b14-ott-9-7105],[@b45-ott-9-7105],[@b46-ott-9-7105] The HPV prevalence was reported to be much more common in oral and anal cancers (58.0% and 80%) than in GC in the present study.[@b45-ott-9-7105],[@b46-ott-9-7105]

Moreover, given insight into the molecular mechanism of gastric oncogenesis, the *p53* gene is suppressor gene. It had been demonstrated that overexpression of p53 resulted in poor prognosis of GC patients.[@b47-ott-9-7105] In the present study, it was found that the role of the *p53* gene was unrelated with HPV prevalence in GC. Five studies included in the present meta-analysis,[@b16-ott-9-7105],[@b22-ott-9-7105],[@b24-ott-9-7105],[@b37-ott-9-7105],[@b40-ott-9-7105] with 354 cases, provided information about the relationship between HPV prevalence and the *p53* gene. The wild-type *p53* gene is a tumor suppressor gene, and mutation of the *p53* gene promoted malignant transformation of human epithelium cells. However, the pooled OR of 1.534 (95% CI =0.752, 3.127) was insignificant.[@b16-ott-9-7105],[@b22-ott-9-7105],[@b24-ott-9-7105],[@b37-ott-9-7105],[@b40-ott-9-7105] Nevertheless, the result was restricted to sample sizes, which could be a source of instability.

The same relationship with the *p53*, *p21*,[@b17-ott-9-7105],[@b24-ott-9-7105],[@b26-ott-9-7105],[@b40-ott-9-7105] and *p16*[@b18-ott-9-7105],[@b35-ott-9-7105],[@b37-ott-9-7105] genes was reported to found with HPV prevalence. Some studies have found that HPV could coinfect with *H*. *pylori*, leading to canceration,[@b25-ott-9-7105] whereas others have found that HPV prevalence was unrelated to *H*. *pylori*.[@b19-ott-9-7105],[@b48-ott-9-7105] One study reported the prevalence of HPV in GC and also tested the telomerase activity.[@b49-ott-9-7105] All of the aforementioned molecular mechanisms suggest that more studies should be conducted.

Finally, the quality of all the 15 case--control studies was assessed based on Newcastle--Ottawa Scale standard conditions. As a result, 13 studies were qualified, and 2 were of good quality.[@b24-ott-9-7105],[@b26-ott-9-7105] Another 15 case-only studies were not assessed yet. Generally, the research included in the present study was appraised as being up to the standard.

Limitations
===========

There are some limitations of this study. First, the included studies were cross-sectional studies; therefore, it could not be affirmed that the prevalence of HPV in GC tissue was caused by the temporal infection or by contamination of tissue samples after GC tumorigenesis. Second, the present study was restricted such that only HPV test methods and research detecting HPV in human GC tissues were included. In addition, Kirkegård et al[@b50-ott-9-7105] preformed an observational cohort study of HPV infection and GC risk in females with cervical conization. Kamangar et al[@b13-ott-9-7105] and Van Doornum et al[@b15-ott-9-7105] searched for HPV antibodies in serum samples from GC patients. None of these three studies were included in the present study, but they had insignificant consequences. Last but not least, among the 30 included suitable searches, 25 were performed in China, which is a substantial source of between-study heterogeneity for the estimated HPV prevalence in GC (a result of meta-regression). The pooled prevalence of HPV was significantly greater in China than in non-Chinese regions (31% vs 9%), which could be partly explained by the very high frequency of GC incidence in Chinese people. However, several studies have indicated that HPV-related cancers were more inclined to occur in the developing countries or economically and sanitationally underdeveloped areas.[@b5-ott-9-7105]

Conclusion
==========

In conclusion, this meta-analysis indicated a high incidence of HPV infection in 1,917 GC patients, with a pooled prevalence of 28.0% and a significantly pooled OR of 7.388 between HPV prevalence and GC risk. Hence, HPV could play a vital role in the pathogenesis of GC, which would be conducive to expounding the potential etiologic significance of gastric tumorigenesis and could provide opinions regarding precautionary measures, but causal relationship can be confirmed only by detecting HPV in the cells of GC precursor lesions (gastric dysplasia or adenoma).
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![The flow diagram of searching and screening process as well as the number of screened, excluded, and included publications.\
**Abbreviations:** GC, gastric cancer; HPV, human papillomavirus.](ott-9-7105Fig1){#f1-ott-9-7105}

![Overall association between HPV infection and GC risk.\
**Note:** Forest plot (weights are from random effects analysis) of the pooled prevalence of HPV positivity in GC.\
**Abbreviations:** GC, gastric cancer; HPV, human papillomavirus; ES, effect size.](ott-9-7105Fig2){#f2-ott-9-7105}

![For 15 case--control studies, the estimates of ORs and their 95% CIs were plotted in a forest plot.\
**Note:** Weights are from random effects analysis.\
**Abbreviations:** CI, confidence interval; OR, odds ratio.](ott-9-7105Fig3){#f3-ott-9-7105}

![The estimates of HPV prevalence and their 95% CIs showed in decimals instead of percentages, plotted in a forest plot.\
**Notes:** Weights are from random effects analysis. All searches were stratified by country, sample size, HPV test method, and materials. Five studies provided age and sex data, and 15 studies provided pathological differentiation; the 5 studies also provided clinical TNM stage information.\
**Abbreviations:** CI, confidence interval; FF, fresh-frozen; FFPE, formalin-fixed paraffin-embedded tissue; GC, gastric cancer; GCA, gastric cardic cancer; HPV, human papillomavirus; PCR, polymerase chain reaction; ISH, in situ hybridization.](ott-9-7105Fig4){#f4-ott-9-7105}

![Begg's test for publication bias (continuity-corrected: *z*=0.30, *P*\>0.767) showing no evident publication bias.\
**Abbreviations:** OR, odds ratio; SE, standard error.](ott-9-7105Fig5){#f5-ott-9-7105}

###### 

The characteristics of all 30 eligible studies

  Author's name                                                               Year   Country   Anatomic site   Language   Sample size (N)   Method   Materials   Case (n)   Control (N)   HPV types         
  --------------------------------------------------------------------------- ------ --------- --------------- ---------- ----------------- -------- ----------- ---------- ------------- ----------- ----- -------------------------
  Saegusa et al[@b34-ott-9-7105]                                              1997   Japan     GC              English    \>50              PCR      FFPE        0          99            NA          NA    HPV16 and HPV18
  Cândido et al[@b48-ott-9-7105],[a](#tfn1-ott-9-7105){ref-type="table-fn"}   2013   Brazil    GC              English    \>50              PCR      FFPE        4          40            10          40    HPV16
  Anwar et al[@b16-ott-9-7105],[a](#tfn1-ott-9-7105){ref-type="table-fn"}     1995   Japan     GC              English    \>50              PCR      FFPE        23         51            2           12    HPV16, HPV18, and HPV33
  Snietura et al[@b35-ott-9-7105]                                             2014   Poland    GC              English    \>50              PCR      FFPE        0          84            NA          NA    14 HPV subtypes
  Sobti et al[@b49-ott-9-7105]                                                2001   India     GC              English    \<50              PCR      FFPE        4          9             NA          NA    NA
  Ding et al[@b18-ott-9-7105]                                                 2010   China     GCC             English    \<50              PCR      FFPE        5          17            NA          NA    HPV16
  Yuan et al[@b31-ott-9-7105]                                                 2013   China     GC              English    \<50              ISH      NA          0          24            NA          NA    13 HR-HPV, 5 LR-HPV
  Koshiol et al[@b33-ott-9-7105]                                              2010   China     GCC             English    \>50              PCR      FFPE        0          144           NA          NA    HPV16 and HPV18
  Ma et al[@b19-ott-9-7105],[a](#tfn1-ott-9-7105){ref-type="table-fn"}        2007   China     GC              English    \>50              PCR      FFPE        15         40            2           40    HPV16
  Cai et al[@b17-ott-9-7105]                                                  2006   China     GC              English    \<50              PCR      FFPE        19         46            NA          NA    HPV16
  Guo et al[@b36-ott-9-7105]                                                  2000   China     GC              Chinese    \<50              PCR      FF          6          41            NA          NA    HPV16 and HPV18
  Sun et al[@b24-ott-9-7105]                                                  2002   China     GC              Chinese    \>50              PCR      NA          28         64            NA          NA    HPV16 and HPV18
  Huang et al[@b37-ott-9-7105]                                                2000   China     GC              Chinese    \>50              ISH      FFPE        39         96            NA          NA    HPV16 and HPV18
  Dong et al[@b20-ott-9-7105],[a](#tfn1-ott-9-7105){ref-type="table-fn"}      1999   China     GC              Chinese    \>50              PCR      NA          10         37            0           20    HPV16 and HPV18
  Du et al[@b21-ott-9-7105]                                                   2000   China     GC              Chinese    \<50              PCR      NA          9          29            NA          NA    HPV16 and HPV18
  Zhu et al[@b30-ott-9-7105],[a](#tfn1-ott-9-7105){ref-type="table-fn"}       2000   China     GC              Chinese    \>50              PCR      FF          11         42            0           42    HPV16 and HPV18
  Wang et al[@b25-ott-9-7105],[a](#tfn1-ott-9-7105){ref-type="table-fn"}      2013   China     GC              Chinese    \>50              PCR      FFPE        20         92            4           86    HPV16
  Xu et al[@b27-ott-9-7105],[a](#tfn1-ott-9-7105){ref-type="table-fn"}        2003   China     GCC             Chinese    \>50              ISH      FFPE        91         176           10          50    HPV16
  Zhang et al[@b39-ott-9-7105]                                                2011   China     GC              Chinese    \>50              PCR      FF          45         62            NA          NA    HPV16 and HPV18
  Liao et al[@b40-ott-9-7105],[a](#tfn1-ott-9-7105){ref-type="table-fn"}      2001   China     GC              Chinese    \>50              ISH      NA          26         50            2           30    HPV16 and HPV18(E6)
  Wei et al[@b26-ott-9-7105]                                                  2006   China     GC              Chinese    \<50              PCR      FFPE        19         46            NA          NA    HPV16
  Zhang et al[@b29-ott-9-7105],[a](#tfn1-ott-9-7105){ref-type="table-fn"}     2001   China     GC              Chinese    \>50              PCR      FF          15         40            0           10    HPV16 and HPV18
  Cao et al[@b51-ott-9-7105]                                                  2005   China     GC              Chinese    \<50              PCR      FF          0          47            NA          NA    NA
  Ma et al[@b22-ott-9-7105],[a](#tfn1-ott-9-7105){ref-type="table-fn"}        2007   China     GCC             Chinese    \>50              PCR      FFPE        32         93            0           21    HPV16 and HPV18
  Zhang et al[@b52-ott-9-7105]                                                2010   China     GCC             Chinese    \>50              PCR      FF          17         165           NA          NA    NA
  Zhou et al[@b32-ott-9-7105],[a](#tfn1-ott-9-7105){ref-type="table-fn"}      1999   China     GC              Chinese    \>50              PCR      FFPE        19         50            0           20    HPV16
  Rong et al[@b23-ott-9-7105],[a](#tfn1-ott-9-7105){ref-type="table-fn"}      2007   China     GCC             Chinese    \<50              PCR      FFPE        16         21            2           21    HPV16
  Yu et al[@b28-ott-9-7105],[a](#tfn1-ott-9-7105){ref-type="table-fn"}        1999   China     GC              Chinese    \>50              PCR      FFPE        30         132           3           104   HPV16 and HPV18
  Sha et al[@b38-ott-9-7105],[a](#tfn1-ott-9-7105){ref-type="table-fn"}       1998   China     GC              Chinese    \>50              PCR      FFPE        27         65            4           65    HPV16
  Su and He[@b53-ott-9-7105],[a](#tfn1-ott-9-7105){ref-type="table-fn"}       2015   China     GC              Chinese    \<50              PCR      NA          1          15            0           15    HPV16 and HPV18

**Note:**

Case--control study.

**Abbreviations:** FF, fresh-frozen; FFPE, formalin-fixed paraffin-embedded tissue; GC, gastric cancer; GCC, gastric cardia cancer; HPV, human papillomavirus; HR-HPV, high-risk types of HPV; ISH, in situ hybridization; LR-HPV, low-risk types of HPV; NA, not available; PCR, polymerase chain reaction.
